Last updated at: (Beijing Time) Friday, December 05, 2003
Joint research on breast & prostate cancers launched in HK
A joint research initiative to study the efficacy of groundbreaking anti-tumor products for breast cancer and prostate cancer was launched here Thursday.
A joint research initiative to study the efficacy of groundbreaking anti-tumor products for breast cancer and prostate cancer was launched here Thursday.
The collaborative study, conducted by the Hong Kong University of Science and Technology (HKUST) and CK Life Sciences International Holdings Inc., will also establish the first-ever pharmacogenomic and pharmacogenetic database for the Chinese population.
With the governmental Innovation and Technology Commission and CK Life Sciences each providing half of the 6.5 million Hong Kong dollars (833,000 US dollars) funding, and HKUST providing its scientific expertise, the research program will be carried out over a period of two and a half years.
The efficacy of CK Life Sciences' anti-tumor products and their immune-enhancing effects will be studied in the first part of the joint research.
The experts of HKUST will also help establish a pharmacogenetic database for the Chinese people to identify the panel of genes involved.